Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.

L S Steelman1, S C Pohnert, J G Shelton

  • 1Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA.

Leukemia
|January 23, 2004
PubMed
Summary

This review discusses key signaling pathways in leukemia development and targeted therapies. It highlights how BCR-ABL oncoprotein dysregulates these pathways and explores strategies to overcome drug resistance in leukemia treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<math></math> -event characterization and rejection in point-contact HPGe detectors.

The European physical journal. C, Particles and fields·2022
Same author

Systematic analysis of GSK-3 signaling pathways in aging of cerebral tissue.

Advances in biological regulation·2018
Same author

First Limit on the Direct Detection of Lightly Ionizing Particles for Electric Charge as Low as e/1000 with the Majorana Demonstrator.

Physical review letters·2018
Same author

Search for Neutrinoless Double-β Decay in ^{76}Ge with the Majorana Demonstrator.

Physical review letters·2018
Same author

Therapeutic targeting of CK2 in acute and chronic leukemias.

Leukemia·2017
Same author

New Limits on Bosonic Dark Matter, Solar Axions, Pauli Exclusion Principle Violation, and Electron Decay from the Majorana Demonstrator.

Physical review letters·2017

Area of Science:

  • Molecular Biology
  • Oncology
  • Signal Transduction

Background:

  • Leukemogenesis involves dysregulation of critical signaling pathways, including JAK/STAT, Raf/MEK/ERK, and PI3K/Akt.
  • The BCR-ABL oncoprotein plays a significant role in initiating and sustaining leukemia by hijacking these pathways.
  • These pathways are crucial for regulating cell cycle progression and apoptosis, processes often aberrant in cancer.

Purpose of the Study:

  • To review the roles of JAK/STAT, Raf/MEK/ERK, and PI3K/Akt signaling pathways in leukemogenesis.
  • To discuss the impact of the BCR-ABL oncoprotein on these pathways and their regulatory functions.
  • To explore targeted small molecule therapies and strategies to overcome drug resistance in leukemia.

Main Methods:

  • Review of existing literature on signal transduction pathways in leukemia.

Related Experiment Videos

  • Analysis of the mechanisms by which BCR-ABL dysregulates cellular processes.
  • Discussion of therapeutic strategies targeting key signaling components and drug resistance.

    • Main Results:

    • Targeted therapies like imatinib mesylate show efficacy against BCR-ABL-driven leukemia (CML).
    • Leukemic cells can develop resistance to targeted therapies through various mechanisms.
    • Alternative strategies, including targeting Ras or using protein destabilizers, can inhibit resistant cell growth.

    Conclusions:

    • Understanding the interplay between BCR-ABL and major signaling pathways is crucial for leukemia therapy.
    • Developing novel therapeutic approaches is essential to combat drug resistance and improve patient outcomes.
    • Targeting multiple signaling components or employing alternative inhibition mechanisms offers promise for treating resistant leukemia.